Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 10 - Sep 15
When focusing on Selenoprotein P (SELENOP), a primary selenium transport protein we found that individuals affected with konzo as compared to their unaffected sibling yielded no significant difference in protein signal in an untargeted analysis
Clinical Evidence and Trial Findings from Current Research The key phase 2 trial (NEJM, 2023) reported mean weight reductions of up to approximately 24.2% at the highest dose over 48 weeks
Related products GHK-Cu Peptide Pen 50mg 40.00 GHK-Cu (Copper Peptide) 50mg Multi-Dose Pen GHK-Cu (Copper Peptide) is a naturally occurring copper-binding peptide that has been studied in laboratory and research settings for its role in various biological processes
Moving ahead, Phase 3 clinical trials will assess its efficacy and tolerability for chronic weight management, obstructive sleep apnea, and knee osteoarthritis in people with obesity and overweight
What the evidence does not establish: Human efficacy at clinically meaningful magnitudes, long-term safety, cardiovascular profile under chronic dosing
Response monitoring through subjective symptom tracking and objective IGF-1 testing after 8-12 weeks guides protocol optimization, confirming adequate stimulation or identifying need for adjustment
US$ 22.51
US$ 26.78
US$ 27.26
%20(1).png)
